Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.

Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A; LEADe Investigators.

Neurology. 2010 Mar 23;74(12):956-64. doi: 10.1212/WNL.0b013e3181d6476a. Epub 2010 Mar 3.

PMID:
20200346
2.

The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.

Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, Hey-Hadavi J, Breazna A, Schindler RJ, Ramos H; LEADe investigators.

Alzheimers Dement. 2008 Mar;4(2):145-53. doi: 10.1016/j.jalz.2008.02.001.

PMID:
18631958
3.

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM; AN1792(QS-21)-201 Study Team.

Neurology. 2005 May 10;64(9):1553-62.

PMID:
15883316

Supplemental Content

Loading ...
Support Center